LCP2 and graft versus host disease: Our data showed that mouse, healthy human and GVHD patient T cells treated with our specific peptide SLP76pTYR had increased FOXP3 expression (and canonical and noncanonical Tregs), suggesting that Itk/SLP76 inhibition could be an alternative approach.